Logo image of PULM

PULMATRIX INC (PULM) Stock Fundamental Analysis

NASDAQ:PULM - Nasdaq - US74584P3010 - Common Stock - Currency: USD

6.47  +0.16 (+2.54%)

After market: 6.64 +0.17 (+2.63%)

Fundamental Rating

3

Taking everything into account, PULM scores 3 out of 10 in our fundamental rating. PULM was compared to 198 industry peers in the Pharmaceuticals industry. PULM has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, PULM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PULM has reported negative net income.
PULM had a negative operating cash flow in the past year.
PULM had negative earnings in each of the past 5 years.
In the past 5 years PULM always reported negative operating cash flow.
PULM Yearly Net Income VS EBIT VS OCF VS FCFPULM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

The Return On Assets of PULM (-96.14%) is worse than 74.75% of its industry peers.
Looking at the Return On Equity, with a value of -106.84%, PULM is in line with its industry, outperforming 40.91% of the companies in the same industry.
Industry RankSector Rank
ROA -96.14%
ROE -106.84%
ROIC N/A
ROA(3y)-61.24%
ROA(5y)-54.83%
ROE(3y)-81.96%
ROE(5y)-75.71%
ROIC(3y)N/A
ROIC(5y)N/A
PULM Yearly ROA, ROE, ROICPULM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

PULM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PULM Yearly Profit, Operating, Gross MarginsPULM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

PULM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PULM has about the same amount of shares outstanding.
Compared to 5 years ago, PULM has more shares outstanding
PULM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PULM Yearly Shares OutstandingPULM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PULM Yearly Total Debt VS Total AssetsPULM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

PULM has an Altman-Z score of -28.12. This is a bad value and indicates that PULM is not financially healthy and even has some risk of bankruptcy.
PULM's Altman-Z score of -28.12 is on the low side compared to the rest of the industry. PULM is outperformed by 87.88% of its industry peers.
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.12
ROIC/WACCN/A
WACC9.67%
PULM Yearly LT Debt VS Equity VS FCFPULM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 10.68 indicates that PULM has no problem at all paying its short term obligations.
PULM has a better Current ratio (10.68) than 85.35% of its industry peers.
PULM has a Quick Ratio of 10.68. This indicates that PULM is financially healthy and has no problem in meeting its short term obligations.
PULM has a better Quick ratio (10.68) than 85.35% of its industry peers.
Industry RankSector Rank
Current Ratio 10.68
Quick Ratio 10.68
PULM Yearly Current Assets VS Current LiabilitesPULM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.20% over the past year.
The Revenue has been growing slightly by 7.05% in the past year.
PULM shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.26% yearly.
EPS 1Y (TTM)32.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.65%
Revenue 1Y (TTM)7.05%
Revenue growth 3Y14.72%
Revenue growth 5Y-0.26%
Sales Q2Q%-99.86%

3.2 Future

Based on estimates for the next years, PULM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.43% on average per year.
Based on estimates for the next years, PULM will show a very strong growth in Revenue. The Revenue will grow by 43.66% on average per year.
EPS Next Y-10%
EPS Next 2Y22.57%
EPS Next 3Y28.64%
EPS Next 5Y23.43%
Revenue Next Year1%
Revenue Next 2Y54.02%
Revenue Next 3Y58.32%
Revenue Next 5Y43.66%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PULM Yearly Revenue VS EstimatesPULM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PULM Yearly EPS VS EstimatesPULM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PULM. In the last year negative earnings were reported.
Also next year PULM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PULM Price Earnings VS Forward Price EarningsPULM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PULM Per share dataPULM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PULM's earnings are expected to grow with 28.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.57%
EPS Next 3Y28.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PULM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULMATRIX INC

NASDAQ:PULM (4/23/2025, 8:00:01 PM)

After market: 6.64 +0.17 (+2.63%)

6.47

+0.16 (+2.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-21 2025-03-21/bmo
Earnings (Next)05-09 2025-05-09
Inst Owners9.28%
Inst Owner Change0%
Ins Owners0.65%
Ins Owner Change0%
Market Cap23.62M
Analysts82.86
Price Target10.2 (57.65%)
Short Float %0.95%
Short Ratio0.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.03
P/FCF N/A
P/OCF N/A
P/B 2.64
P/tB 2.64
EV/EBITDA N/A
EPS(TTM)-2.62
EYN/A
EPS(NY)-5.05
Fwd EYN/A
FCF(TTM)-3.04
FCFYN/A
OCF(TTM)-2.94
OCFYN/A
SpS2.14
BVpS2.45
TBVpS2.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -96.14%
ROE -106.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.24%
ROA(5y)-54.83%
ROE(3y)-81.96%
ROE(5y)-75.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.49%
Cap/Sales 5.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.68
Quick Ratio 10.68
Altman-Z -28.12
F-Score4
WACC9.67%
ROIC/WACCN/A
Cap/Depr(3y)64.52%
Cap/Depr(5y)80.64%
Cap/Sales(3y)5.28%
Cap/Sales(5y)4.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.65%
EPS Next Y-10%
EPS Next 2Y22.57%
EPS Next 3Y28.64%
EPS Next 5Y23.43%
Revenue 1Y (TTM)7.05%
Revenue growth 3Y14.72%
Revenue growth 5Y-0.26%
Sales Q2Q%-99.86%
Revenue Next Year1%
Revenue Next 2Y54.02%
Revenue Next 3Y58.32%
Revenue Next 5Y43.66%
EBIT growth 1Y51.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.96%
OCF growth 3YN/A
OCF growth 5YN/A